Nurix Therapeutics, Inc.
NASDAQ:NRIX
Overview | Financials
| Company Name | Nurix Therapeutics, Inc. |
| Symbol | NRIX |
| Currency | USD |
| Price | 9.7 |
| Market Cap | 741,559,180 |
| Dividend Yield | 0% |
| 52-week-range | 8.18 - 29.56 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Arthur T. Sands M.D., Ph.D. |
| Website | https://www.nurixtx.com |
An error occurred while fetching data.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD








